Roche Holding AG (RHHBY) Monday said Phase 3 STARGLO study of Columvi met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Patients who were treated with Columvi in combination with gemcitabine and oxaliplatin chemotherapy (GemOx) lived longer than those who were treated with MabThera/Rituxan in combination with GemOx.
Columvi has already received accelerated approval by the U.S. Food and Drug Administration and conditional marketing authorization from the European Commission to treat people with R/R DLBCL after two or more lines of systemic therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.